View all newsletters
Receive our newsletter – data, insights and analysis delivered to you

Sometimes, You Have to Move to Go Forward

PhenoSwitch Biosource is proud to announce that it will be operating from a new space in the beautiful Sherbrooke, Quebec, Canada.

With its growing client base and an urgent need for privacy, the company needed to find a new home for the TTOF5600, as well as it’s new fellow mass spectrometers.

Being incubated as a biotech startup is absolutely crucial as it gives young companies a place to operate and various degrees of guidance. However, it does come with some restrictions about space, common areas, internal policies on the building, privacy issues, and so on.

Therefore, as PhenoSwitch Biosource’s growth reached a critical point in the last year or so, it had to make a move and find its own place. The company will dearly miss the friends and colleagues it met at the Institut de Pharmacologie and will be forever grateful for their help and support.

New space, new lab, new opportunities

This move is the beginning of a very exciting phase for PhenoSwitch Biosource. The company will now be able to make vital modifications to its workspace to accommodate several new mass spectrometers.

The company will be releasing the news about its new machines as they come in, but it can already tell you that it has been able to put its hands on a brand new LCMS-8060, from Shimadzu. This instrument will bring a lot of sensitivity, stability and throughput to the company and is the first of its additional MS.

The LC-8060 in all it’s glory

What PahoSwitch Biosource’s relocation means for its clients:

  • More machines – Moving in a bigger place opens a world of possibilities, the first being that the company can now house many more mass spectrometers. It indeed acquired two new machines from Shimadzu and are currently working towards upgrading its offer with a newer version of the TripleTOF from Sciex. The LCMS-8060 and the LCMS-9030 from Shimadzu will increase PhanoSwitch Biosource’s throughput capabilities by a lot. It should also facilitate the transfer from metabolite identification to targeted quantification, which will give us a clear edge on the metabolomics market. The addition of a TripleTOF 6600 to its fleet will push its sensibility and quantification power for label-free quantitative proteomics experiments even further. More machine also means that we will no longer have down times if one of our machines breaks
  • Shorter and honoured estimated time of arrival (ETA) – Having more machines will most definitely mean the need for an increase in staff. With a bigger team and more machines to process samples, the company expects both a shorter and respected ETA, as well as more thorough monitoring of projects
  • Overall improvements – With the move on the horizon, PhanoSwitch Biosource thought that it would be a good time for it to review its internal processes and the way it handles everything related to its clients. This is why, for the past months, the company has redesigned its client’s journey to make it simpler and more efficient, while making it more enjoyable for clients. The company is still refining the details of this process, but it expects to have it fully operational in the following weeks.

On a final note

There you have it. This is PhenoSwitch Biosource’s final update on the move, and you can consider that it is now fully operational, with a working TripleTOF 5600 and LCMS-8060.

As stated above, the company will be receiving two additional QTOF systems that should be up and running by mid-spring. It will be releasing blog posts related to the LCMS-8060 as well as these two QTOFs in the near future.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena